Sophia Antipolis, France

MEDIAN will demonstrate its Lesion Management Solutions (LMS) and discuss the results of its abstract at Booth #3097, Hall B

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the 2013 ASCO annual conference, to be held next May 31 – June 4, in Chicago, IL, USA (exhibition dates: June 1-3).

During ASCO, the world’s premier oncology conference, representatives from MEDIAN will be present at Booth #3097, Hall B to give demonstrations of their Lesion Management Solutions software and to discuss their abstract, ‘Determination of thresholds for the assessment of response to therapy relying on volume-based tumor burden in pulmonary CT images’. Today, Response Evaluation Criteria In Solid Tumors (RECIST) provide indications on tumor burden, based on the measurement of the Longest Axial Diameter of malignant tumors. RECIST enables the assessment of response to therapy of cancer patients enrolled in clinical trials. However, a growing medical community now believes that RECIST is limited because it relies on an approximate estimate of the tumor burden. This limitation could be overcome by using tumor volume as another imaging biomarker, reflecting more accurate tumor burden. The study performed by MEDIAN in collaboration with clinical sites based in France and Germany, deals with the utilization of tumor volume as an indicator of response to therapy and more specifically, with the applicable threshold values enabling physicians to diagnose whether or not the patient responds to therapy. The study is based on published data from the Quantitative Imaging Biomarker Alliance (QIBA) about the inter-reader measurement variability and on clinical data from a retrospective study on pulmonary cancer patients (NSCLC) followed with CT imaging.

Download ASCO_2013_participation.pdf